{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:17:03Z","timestamp":1788545823872,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The two oncogenic human gammaherpesviruses, Kaposi sarcoma-associated herpesvirus (KSHV) and Epstein\u2013Barr virus (EBV), both downregulate immune surface molecules, such as MHC-I, ICAM-1, and B7-2, enabling them to evade T-cell and natural killer cell immunity. Both also either encode for human cyclin homologues or promote cellular cyclin activity, and this has been shown to be important for proliferation and survival of gammaherpesvirus-induced tumors. CDK4\/6 inhibitors, which are approved for certain breast cancers, have been shown to enhance expression of MHC-I in cell lines and murine models of breast cancer, and this was attributed to activation of interferons by endogenous retrovirus elements. However, it was not known if this would occur in gammaherpesvirus-induced tumors in which interferons are already activated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Multiple KSHV\/EBV-infected cell lines\u00a0were treated with CDK4\/6 inhibitors. The growth of viable cells and expression of surface markers was assessed. T cell activation stimulated by the treated cells was assayed by a T-cell activation bioassay. Both viral and host gene expression was surveyed using RT-qPCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three CDK4\/6 inhibitors, abemaciclib, palbociclib, and ribociclib, inhibited cell growth in KSHV-induced primary effusion lymphoma (PEL) and EBV positive Burkitt\u2019s lymphoma (BL) cell lines, and KSHV-infected human umbilical vein endothelial cells (HUVECs). Moreover, CDK4\/6 inhibitors increased mRNA and surface expression of MHC-I in all three and prevented downregulation of MHC-I surface expression during lytic replication in KSHV-infected cells. CDK4\/6 inhibitors also variably increased mRNA and surface expression of ICAM-1 and B7-2 in the tested lines. Abemaciclib also significantly enhanced T-cell activation induced by treated PEL and BL cells. Certain gammaherpesvirus genes as well as endogenous retrovirus (ERV) 3\u20131 genes were enhanced by CDK4\/6 inhibitors in most PEL and BL lines and this enhancement was associated with expression of gamma interferon-induced genes including MHC-I.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These observations provide evidence that CDK4\/6 inhibitors can induce expression of surface immune markers MHC-I, B7-2, and ICAM-1 in gammaherpesvirus-infected cell lines and induce virus-specific immunity. They can thus thwart virus-induced immune evasion. These effects, along with their direct effects on KSHV- or EBV-induced tumors, provide a rational for the clinical testing of these drugs in these tumors.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-022-03400-z","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T11:09:48Z","timestamp":1652440188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["CDK4\/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules"],"prefix":"10.1186","volume":"20","author":[{"given":"Yiquan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie M.","family":"Heape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-1395","authenticated-orcid":false,"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"22","key":"3400_CR1","first-page":"2145","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(22):2145.","journal-title":"N Engl J Med"},{"issue":"16","key":"3400_CR2","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1097\/QAD.0000000000000808","volume":"29","author":"C de Martel","year":"2015","unstructured":"de Martel C, Shiels MS, Franceschi S, Simard EP, Vignat J, Hall HI, et al. Cancers attributable to infections among adults with HIV in the United States. AIDS. 2015;29(16):2173\u201381.","journal-title":"AIDS"},{"key":"3400_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe C, Rickinson A. The global landscape of EBV-associated tumors. Front Oncol. 2019;9:713.","journal-title":"Front Oncol"},{"key":"3400_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3389\/fmicb.2012.00066","volume":"3","author":"A Ashizawa","year":"2012","unstructured":"Ashizawa A, Higashi C, Masuda K, Ohga R, Taira T, Fujimuro M. The Ubiquitin system and Kaposi\u2019s sarcoma-associated herpesvirus. Front Microbiol. 2012;3:66.","journal-title":"Front Microbiol"},{"issue":"11","key":"3400_CR5","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1128\/JVI.74.11.5300-5309.2000","volume":"74","author":"S Ishido","year":"2000","unstructured":"Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Downregulation of major histocompatibility complex class I molecules by Kaposi\u2019s sarcoma-associated herpesvirus K3 and K5 proteins. J Virol. 2000;74(11):5300\u20139.","journal-title":"J Virol"},{"issue":"3","key":"3400_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S1074-7613(00)00036-4","volume":"13","author":"S Ishido","year":"2000","unstructured":"Ishido S, Choi JK, Lee BS, Wang C, DeMaria M, Johnson RP, et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi\u2019s sarcoma-associated herpesvirus K5 protein. Immunity. 2000;13(3):365\u201374.","journal-title":"Immunity"},{"issue":"14","key":"3400_CR7","doi-asserted-by":"publisher","first-page":"8051","DOI":"10.1073\/pnas.140129797","volume":"97","author":"L Coscoy","year":"2000","unstructured":"Coscoy L, Ganem D. Kaposi\u2019s sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci USA. 2000;97(14):8051\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"3400_CR8","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1128\/JVI.07216-11","volume":"86","author":"F Lu","year":"2012","unstructured":"Lu F, Tsai K, Chen HS, Wikramasinghe P, Davuluri RV, Showe L, et al. Identification of host-chromosome binding sites and candidate gene targets for Kaposi\u2019s sarcoma-associated herpesvirus LANA. J Virol. 2012;86(10):5752\u201362.","journal-title":"J Virol"},{"issue":"6","key":"3400_CR9","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1182\/blood.V90.6.2390","volume":"90","author":"R Zeidler","year":"1997","unstructured":"Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S, et al. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood. 1997;90(6):2390\u20137.","journal-title":"Blood"},{"issue":"4","key":"3400_CR10","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.4049\/jimmunol.0803218","volume":"182","author":"D Horst","year":"2009","unstructured":"Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, et al. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol. 2009;182(4):2313\u201324.","journal-title":"J Immunol"},{"issue":"8","key":"3400_CR11","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1084\/jem.20070256","volume":"204","author":"AD Hislop","year":"2007","unstructured":"Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, et al. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med. 2007;204(8):1863\u201373.","journal-title":"J Exp Med"},{"issue":"1","key":"3400_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000255","volume":"5","author":"J Zuo","year":"2009","unstructured":"Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, Ressing ME, et al. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009;5(1): e1000255.","journal-title":"PLoS Pathog"},{"issue":"2","key":"3400_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1006\/viro.2002.1716","volume":"304","author":"S Salek-Ardakani","year":"2002","unstructured":"Salek-Ardakani S, Arrand JR, Mackett M. Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV. Virology. 2002;304(2):342\u201351.","journal-title":"Virology"},{"issue":"10","key":"3400_CR14","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1182\/blood-2004-05-1798","volume":"104","author":"A Jarviluoma","year":"2004","unstructured":"Jarviluoma A, Koopal S, Rasanen S, Makela TP, Ojala PM. KSHV viral cyclin binds to p27KIP1 in primary effusion lymphomas. Blood. 2004;104(10):3349\u201354.","journal-title":"Blood"},{"issue":"1","key":"3400_CR15","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1038\/s41467-018-05506-9","volume":"9","author":"M Manzano","year":"2018","unstructured":"Manzano M, Patil A, Waldrop A, Dave SS, Behdad A, Gottwein E. Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma. Nat Commun. 2018;9(1):3263.","journal-title":"Nat Commun"},{"issue":"2","key":"3400_CR16","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1128\/JVI.05923-11","volume":"86","author":"DJ Hughes","year":"2012","unstructured":"Hughes DJ, Marendy EM, Dickerson CA, Yetming KD, Sample CE, Sample JT. Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency. J Virol. 2012;86(2):1034\u201345.","journal-title":"J Virol"},{"issue":"11","key":"3400_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/35041064","volume":"2","author":"PM Ojala","year":"2000","unstructured":"Ojala PM, Yamamoto K, Castanos-Velez E, Biberfeld P, Korsmeyer SJ, Makela TP. The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol. 2000;2(11):819\u201325.","journal-title":"Nat Cell Biol"},{"issue":"50","key":"3400_CR18","doi-asserted-by":"publisher","first-page":"E3473","DOI":"10.1073\/pnas.1202637109","volume":"109","author":"CM Tsang","year":"2012","unstructured":"Tsang CM, Yip YL, Lo KW, Deng W, To KF, Hau PM, et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc Natl Acad Sci USA. 2012;109(50):E3473\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3400_CR19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4049\/jimmunol.155.3.1047","volume":"155","author":"L Arvanitakis","year":"1995","unstructured":"Arvanitakis L, Yaseen N, Sharma S. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. J Immunol. 1995;155(3):1047\u201356.","journal-title":"J Immunol"},{"issue":"7","key":"3400_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O'Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417\u201330.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3400_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317\u201331.","journal-title":"Drugs"},{"issue":"2","key":"3400_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8(2):216\u201333.","journal-title":"Cancer Discov"},{"issue":"7668","key":"3400_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471.","journal-title":"Nature"},{"issue":"11","key":"3400_CR24","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, et al. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2978\u201394.","journal-title":"Cell Rep"},{"issue":"31","key":"3400_CR25","doi-asserted-by":"publisher","first-page":"50342","DOI":"10.18632\/oncotarget.17960","volume":"8","author":"DA Davis","year":"2017","unstructured":"Davis DA, Mishra S, Anagho HA, Aisabor AI, Shrestha P, Wang V, et al. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget. 2017;8(31):50342\u201358.","journal-title":"Oncotarget"},{"issue":"2","key":"3400_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1546544","volume":"8","author":"DA Davis","year":"2019","unstructured":"Davis DA, Shrestha P, Aisabor AI, Stream A, Galli V, Pise-Masison CA, et al. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. Oncoimmunology. 2019;8(2): e1546544.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3400_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009091","volume":"17","author":"P Shrestha","year":"2021","unstructured":"Shrestha P, Davis DA, Jaeger HK, Stream A, Aisabor AI, Yarchoan R. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7\u20132. PLoS Pathog. 2021;17(1): e1009091.","journal-title":"PLoS Pathog"},{"issue":"23","key":"3400_CR28","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1158\/1078-0432.CCR-18-1256","volume":"24","author":"M Dowless","year":"2018","unstructured":"Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, et al. abemaciclib is active in preclinical models of ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling. Clin Cancer Res. 2018;24(23):6028\u201339.","journal-title":"Clin Cancer Res"},{"key":"3400_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0065-230X(06)97004-3","volume":"97","author":"G Miller","year":"2007","unstructured":"Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. Lytic cycle switches of oncogenic human gammaherpesviruses. Adv Cancer Res. 2007;97:81\u2013109.","journal-title":"Adv Cancer Res"},{"issue":"12","key":"3400_CR30","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","volume":"13","author":"CJ Sherr","year":"1999","unstructured":"Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501\u201312.","journal-title":"Genes Dev"},{"issue":"3","key":"3400_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.semcancer.2009.02.010","volume":"19","author":"SN Pantry","year":"2009","unstructured":"Pantry SN, Medveczky PG. Epigenetic regulation of Kaposi\u2019s sarcoma-associated herpesvirus replication. Semin Cancer Biol. 2009;19(3):153\u20137.","journal-title":"Semin Cancer Biol"},{"issue":"37","key":"3400_CR32","doi-asserted-by":"publisher","first-page":"E5199","DOI":"10.1073\/pnas.1503806112","volume":"112","author":"A Saha","year":"2015","unstructured":"Saha A, Jha HC, Upadhyay SK, Robertson ES. Epigenetic silencing of tumor suppressor genes during in vitro Epstein-Barr virus infection. Proc Natl Acad Sci USA. 2015;112(37):E5199\u2013207.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"3400_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/jnci\/dji113","volume":"97","author":"R Van Dross","year":"2005","unstructured":"Van Dross R, Yao S, Asad S, Westlake G, Mays DJ, Barquero L, et al. Constitutively active K-cyclin\/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells. J Natl Cancer Inst. 2005;97(9):656\u201366.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"3400_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","volume":"20","author":"G Petroni","year":"2020","unstructured":"Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol. 2020;20(11):669\u201379.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3400_CR35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/1078-0432.CCR-18-1967","volume":"25","author":"JLF Teh","year":"2019","unstructured":"Teh JLF, Aplin AE. Arrested developments: CDK4\/6 inhibitor resistance and alterations in the tumor immune microenvironment. Clin Cancer Res. 2019;25(3):921\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3400_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/icb.1975.3","volume":"53","author":"KJ Lafferty","year":"1975","unstructured":"Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975;53(1):27\u201342.","journal-title":"Aust J Exp Biol Med Sci"},{"key":"3400_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","volume":"14","author":"DJ Lenschow","year":"1996","unstructured":"Lenschow DJ, Walunas TL, Bluestone JA. CD28\/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233\u201358.","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"3400_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1172\/JCI12432","volume":"107","author":"L Coscoy","year":"2001","unstructured":"Coscoy L, Ganem D. A viral protein that selectively downregulates ICAM-1 and B7\u20132 and modulates T cell costimulation. J Clin Invest. 2001;107(12):1599\u2013606.","journal-title":"J Clin Invest"},{"issue":"4","key":"3400_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3400_CR40","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-15-2347","volume":"76","author":"M Acevedo","year":"2016","unstructured":"Acevedo M, Vernier M, Mignacca L, Lessard F, Huot G, Moiseeva O, et al. A CDK4\/6-dependent epigenetic mechanism protects cancer cells from PML-induced senescence. Cancer Res. 2016;76(11):3252\u201364.","journal-title":"Cancer Res"},{"key":"3400_CR41","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3389\/fimmu.2017.01707","volume":"8","author":"EA Hemann","year":"2017","unstructured":"Hemann EA, Gale M Jr, Savan R. Interferon lambda genetics and biology in regulation of viral control. Front Immunol. 2017;8:1707.","journal-title":"Front Immunol"},{"issue":"3","key":"3400_CR42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/imm.13235","volume":"162","author":"SX Cho","year":"2021","unstructured":"Cho SX, Vijayan S, Yoo JS, Watanabe T, Ouda R, An N, et al. MHC class I transactivator NLRC5 in host immunity, cancer and beyond. Immunology. 2021;162(3):252\u201361.","journal-title":"Immunology"},{"key":"3400_CR43","first-page":"41","volume":"7","author":"J Satoh","year":"2013","unstructured":"Satoh J, Tabunoki H. A comprehensive profile of ChIP-Seq-based STAT1 target genes suggests the complexity of STAT1-mediated gene regulatory mechanisms. Gene Regul Syst Bio. 2013;7:41\u201356.","journal-title":"Gene Regul Syst Bio"},{"issue":"12","key":"3400_CR44","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/s41591-018-0217-1","volume":"24","author":"M Cerezo","year":"2018","unstructured":"Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 2018;24(12):1877\u201386.","journal-title":"Nat Med"},{"issue":"1\u20132","key":"3400_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jneuroim.2013.02.010","volume":"258","author":"H Huang","year":"2013","unstructured":"Huang H, Ito K, Dangond F, Dhib-Jalbut S. Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation. J Neuroimmunol. 2013;258(1\u20132):27\u201331.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"3400_CR46","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.leu.2402903","volume":"17","author":"C Delfini","year":"2003","unstructured":"Delfini C, Centis F, Tabellini L, Nicolini G, Visani G. Interferon-alpha modulates the immune response enhancing B7\u20131 and B7\u20132 costimulatory molecules and T8 lymphocytes in chronic myeloid leukemia. Leukemia. 2003;17(5):983\u20134 (author reply 5).","journal-title":"Leukemia"},{"issue":"34","key":"3400_CR47","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","volume":"34","author":"MN Polizzotto","year":"2016","unstructured":"Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, et al. Pomalidomide for symptomatic Kaposi\u2019s sarcoma in people with and without HIV infection: a phase I\/II study. J Clin Oncol. 2016;34(34):4125\u201331.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3400_CR48","doi-asserted-by":"publisher","first-page":"e002097","DOI":"10.1136\/jitc-2020-002097","volume":"9","author":"K Lurain","year":"2021","unstructured":"Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, et al. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin\u2019s lymphoma. J Immunother Cancer. 2021;9(2):e002097.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"3400_CR49","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","volume":"5","author":"TS Uldrick","year":"2019","unstructured":"Uldrick TS, Goncalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study. JAMA Oncol. 2019;5(9):1332\u20139.","journal-title":"JAMA Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03400-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T04:33:43Z","timestamp":1675571623000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03400-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03400-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was presented in part as an abstracts and poster at the 23rd International Workshop on Kaposi's Sarcoma Herpesvirus & Related Agents, Virtual meeting, (2021) and the 17th International Conference on Malignancies in HIV\/AIDS, NIH, Bethesda, MD (2019).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R. Yarchoan reports receiving\u00a0research\u00a0support from Celgene (now Bristol Myers Squibb) through CRADAs with the NCI. Dr. Yarchoan also reports receiving drugs for\u00a0clinical\u00a0trials from Merck, EMD-Serano, Eli Lilly, and CTI BioPharma\u00a0through CRADAs\u00a0with the NCI, and he has received drug supply for laboratory research from Janssen Pharmaceuticals. R. Yarchoan is a co-inventor on US Patent 10,001,483 entitled \"Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds and uses of biomarkers.\"\u00a0R. Yarchoan is also a\u00a0coinventor on patents on a peptide vaccine for HIV and on the treatment of Kaposi sarcoma with IL12, and an immediate family member of R. Yarchoan is a co-inventor on patents related to internalization of target receptors, on KSHV viral IL-6, and on the use of calreticulin and calreticulin fragments to inhibit angiogenesis. All rights, title, and interest to these patents have been or should by law be assigned to the U.S. Department of Health and Human Services; the government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502).\u00a0No potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}